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Genetics of Alzheimer disease in the pre-GWAS era
Early-onset familial Alzheimer disease
Alzheimer disease (AD), the most common dementia, 
currently aﬀ  ects an estimated 35 million patients world-
wide [1] and is characterized by extracellular accumu  la-
tion of the amyloid β (Aβ) peptide in senile plaques and 
intracellular accumulation of the abnormally hyper-
phosphorylated tau forming neuroﬁ  brillary tangles in the 
brain [2,3]. Th  ere is evidence from familial aggregation, 
transmission patterns, and twin studies that AD has a 
substantial genetic component that has an estimated 
heritability of 58% to 79% [4], and the lifetime risk of AD 
in ﬁ  rst-degree relatives of patients may be twice that of 
the general population [5]. Families with autosomal 
dominant transmission of AD were described in the 
literature in the 1980s [6]. In the early 1990s, segregation 
analysis studies suggested the presence of Mendelian, 
autosomal, dominant risk factors under  lying the risk of 
early-onset AD, whereas a more complex model possibly 
involving polygenes and environmental factors emerged 
for late-onset AD (LOAD) [7,8]. Th  e identiﬁ  cation  of 
homology in the Aβ peptide isolated from brains of 
patients with AD and trisomy 21 (Down syndrome) and 
localization of the amyloid precursor protein (APP) to 
chromosome 21 [9,10], where linkage to disease risk was 
mapped in early-onset familial AD (EOFAD) families 
[11,12], led to the discovery of ﬁ  rst autosomal dominant 
missense mutations in APP segre  gat  ing with disease risk 
[13]. Th  is was followed by identi  ﬁ  cations of autosomal 
dominant EOFAD mutations in the presenilin 1 (PSEN1) 
[14] and PSEN2 [15,16] genes, on chromosomes 14 and 1, 
respectively. Th  e summary of EOFAD mutations is 
maintained at the Alzheimer Disease and Frontotemporal 
Dementia Mutation Data  base [17,18]. Accordingly, there 
are currently 32 mutations in APP, 177 in PSEN1, and 14 
in  PSEN2, identiﬁ   ed in 86, 392, and 23 families, 
respectively. Collectively, the EOFAD mutations in these 
three genes account for less than 1% of all AD.
Aβ, the major peptide constituent of senile plaques, is 
cleaved from APP ﬁ  rst by β-secretase, then by the γ-
secretase complex, of which presenilin is a required 
compo  nent. Despite the rarity of APP and PSEN muta-
tions, their functional evaluation in transfected cells 
[19,20], transgenic animals [21,22], and human plasma 
[23] identiﬁ  ed elevations in Aβ levels, increased Aβ42/
Aβ40 ratio, or ﬁ   brillogenesis, which constituted the 
cornerstone of the amyloid cascade hypothesis [24]. 
Accordingly, increases in the toxic forms of Aβ lead to a 
cascade of events – including inﬂ  ammation,  synaptic 
loss, ionic imbalance, and abnormal phosphorylation of 
proteins (including tau) – culminating in cell death and 
underlying clinical dementia. Th  ere exist alternative 
hypo  theses suggesting tau [25] or dominant negative loss 
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mechanisms underlying AD.
Late-onset Alzheimer disease
Th  e identiﬁ   cation of a chromosome 19 risk locus in 
LOAD families [27] was followed by the discovery of a 
higher frequency of the APOE ε4 allele in LOAD patients 
compared with controls [28,29]. APOE is a component of 
senile plaques [30], binds Aβ [31], can inﬂ  uence neuritic 
plaque formation in transgenic mouse models of AD in 
an isoform-speciﬁ   c fashion [32], and is thought to 
contribute to both Aβ clearance and deposition in the 
brain [33]. In vitro and in vivo studies also suggest a role 
for  APOE in isoform-speciﬁ  c synaptogenesis and cog-
nition, neurotoxicity, tau hyperphosphorylation, neuro-
inﬂ   ammation, and brain metabolism, although these 
non-Aβ-related mechanisms require further investigation 
[34]. Unlike the EOFAD mutations that are fully pene-
trant,  APOE ε4 is a genetic risk factor that is neither 
necessary nor suﬃ   cient for the development of AD (see 
[35] for review of APOE in LOAD). Th   e odds that APOE 
ε3/ε4 genotype carriers have AD is estimated to be two to 
four times greater than that of APOE ε3/ε3 carriers, 
according to population-based association studies in 
subjects of European origin. Th   e odds ratio (OR) 
increases to approximately 6 to 30 in the APOE ε4/ε4 
genotype carriers. Although there is evidence of a risk 
eﬀ  ect of APOE ε4 in non-Europeans, the estimated eﬀ  ect 
sizes are smaller with less consistent results in African-
American and Hispanic subjects, which may suggest 
diﬀ  erent underlying genetic or environmental factors or 
both for these ethnic groups. Th  e eﬀ  ect  of  APOE ε4 
appears to be age-dependent, with the strongest eﬀ  ect 
observed before age 70. Th   e use of APOE as a diagnostic 
[36] or predictive factor in clinical practice is not 
warranted. Population attributable risk (PAR) of AD due 
to a genetic factor describes the diﬀ  erence in rate of AD 
in the population between those who are carriers of the 
genetic risk versus those who are not. Another way to 
consider PAR is the amount of decrease that would be 
observed in the incidence of AD if the genetic factor 
could be eliminated. It is important to note that the PAR 
due to a combination of risk factors is usually smaller 
than the sum of PARs from multiple risk factors because 
a person with disease may have more than one risk factor 
(that is, the cause of disease in any given case may be 
attributable to more than one factor). Th  e estimated 
LOAD PAR for APOE is 20% to 70% [4,35]. Th  is  relatively 
wide range of PAR estimates for APOE likely reﬂ  ects the 
diﬀ  erence in study types (population-based versus clinic-
based, longitudinal versus cross-sectional), age range of 
the population, and other characteristics such as family 
history. PAR esti  mates may have an upward bias in 
family-based studies and younger populations given that 
APOE has a stronger eﬀ   ect in younger ages (from 
younger than age 70 to eighties) and longitudinal studies 
may provide more accurate estimates of PAR of APOE 
where estimates of 20% were obtained [35,37,38]. Statis-
tical approaches suggesting the presence of AD loci in 
addition to APOE [39] led to intensive research eﬀ  orts in 
the genetics of LOAD.
Linkage and smaller-scale association studies
Generation of the genetic and physical map of the human 
genome [40] largely based on polymorphic tandem 
repeat regions led to the ﬁ  rst-generation genome-wide 
scans in AD as well as many other diseases. Ten inde  pen-
dent whole-genome linkage and four association studies 
in AD were completed using microsatellite markers 
(reviewed in [35]) between 1997 and 2006. Th  ese  studies 
typically used approximately 200 to 400 micro  satellite 
markers, covering the genome at every 5 to 16 centi-
morgans (1 cM is approximately equal to 1 million base 
pairs). Th   e whole-genome linkage studies were conducted 
in AD families or sibships collectively composed of about 
100 to 2,000 subjects. Whole-genome association studies 
were conducted on AD case-control series composed of a 
small number of subjects (n is approximately equal to 10 
to 210, including an approximately equal number of AD 
patients and controls). Th  ese studies were hypothesis-
free (or hypothesis-generating) in that they provided a 
survey of the whole genome without requiring any prior 
knowledge or theory about the genes/genomic regions 
for their role in AD. All of the studies that were done in 
subjects of European origin identiﬁ  ed the APOE region 
on chromo  some 19 as a risk region in AD. Importantly, 
however, they also detected other genetic regions, at 
times with a signal stronger than that of APOE. Some of 
these regions were detected in multiple independent 
studies, strongly suggesting the presence of non-APOE 
genetic factors underlying the risk of AD. Loci on 
chromosomes 6, 9, 10, and 12 [29,35] yielded multiple, 
independent, strong signals that led to subsequent ﬁ  ne-
mapping eﬀ  orts, which have proven diﬃ   cult due to the 
typically large regions identiﬁ  ed in these studies covering 
tens of millions of base pairs. Nonetheless, these ﬁ  ndings 
generated positional and functional candidate genes that 
were assessed in association studies.
Th  e  identiﬁ  cation of single-nucleotide polymorphisms 
(SNPs) in the human genome [41] and development of 
high-throughput SNP genotyping technologies galva-
nized such studies to understand the underlying genetics 
of common, complex diseases. Since the 1990s, more 
than 1,000 association studies have been carried out in 
nearly 600 AD candidate genes, regularly updated in the 
AlzGene website [42], which is a database of genetic 
linkage and association studies in AD [29]. Some of the 
AD candidate gene studies led to the identiﬁ  cation of 
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and evidence of association with AD risk in relatively 
large series. Sortilin-related receptor (SORL1) [43] and 
calcium homeostasis modulator 1 (CALHM1) [44] are 
two such genes. Variations in both genes were assessed in 
more than 3,000 to 4,000 subjects from multiple 
independent family-based or case control series in these 
studies. Furthermore, considerable functional analyses 
implicated SORL1 in APP sorting [43] and CALHM1 in 
calcium signaling that also inﬂ   uences Aβ levels [44]. 
Despite these initial results and some supportive follow-
up studies from independent groups, there have also 
been reports of negative or weaker association for these 
genes summarized in AlzGene. Inconsistent replication 
of original association ﬁ  ndings has been the rule rather 
than the exception in AD, except for APOE, and even for 
candidate genes with convincing functional data and 
thorough genetic assessment with positive association 
results in the initial study.
Potential problems in candidate gene association 
studies of AD and proposed solutions are discussed 
elsewhere [29,45,46] and will be brieﬂ  y mentioned here. 
Th   e potential causes for inconsistent replication of asso-
cia  tion studies in AD (and other common, complex 
diseases) include initial false-positive results, false-
negative follow-up results, and heterogeneity in pheno-
type, genotype, or environment. Multiple testing, 
population stratiﬁ   cation, genotyping errors, and initial 
small sample size are potential reasons for false-positive 
ﬁ  ndings in the original study. Underpowered studies that 
are too small to detect a modest eﬀ  ect size can lead to 
false-negative follow-up studies. Meta-analyses of asso-
cia  tion studies in AD [29] and other common diseases 
reveal modest estimated eﬀ  ect sizes with ORs of less than 
2.0 (or greater than 0.5 for protective alleles) [47]. It is 
estimated that thousands to tens of thousands of subjects 
are required to have suﬃ   cient power to detect such eﬀ  ect 
sizes, a prerequisite that has typically not been fulﬁ  lled 
for many association studies in AD until recently.
Genetic heterogeneity in the form of both diﬀ  erent 
disease genes and diﬀ  erent alleles (in the same genes) 
underlying disease risk could account for failure of 
replication in association studies of common, complex 
diseases. Th   e situation becomes even more complicated 
when potential gene-gene and gene-environment inter-
actions are considered. Finally, given that association 
studies rely on the existing linkage disequilibrium (LD) 
between the genotyped markers and the actual functional 
disease susceptibility variant (typically not genotyped), 
heterogeneity in the extent of this LD between diﬀ  erent 
study populations could also account for inconsistent 
results between diﬀ   erent studies. Study of isolated 
populations or disease groups or both with distinct or 
extreme phenotypes could be used in an attempt to 
decrease genic, allelic, phenotypic, and environmental 
heterogeneity but may come at the expense of limited 
generalizability of study results. Use of multiple, 
informative, putative functional markers; testing for and 
correcting population substructure; and use of bio-
logically relevant, quantitative phenotypes (endopheno-
types) in addition to the disease phenotype are additional 
approaches to address heterogeneity and potentially to 
increase power in association studies. Testing multiple 
independent series internally prior to publication, 
supplementing genetic data with functional assays, and 
choice of candidate genes and variants with increased a 
priori  probability of association based on biology and 
position of the gene can increase the probability of 
success in association studies of common diseases such 
as AD.
Genetics of Alzheimer disease in the GWAS era
Th   e International HapMap Project, launched in October 
2002, led to the generation of a database of the common 
variations (deﬁ  ned as minor allele frequency of greater 
than 0.05) and the underlying LD structure in the human 
genome [48,49] that provided the foundation for the 
genome-wide association studies (GWASs) that use high-
throughput genotyping platforms composed of common 
SNP markers that tag a subset of the known common 
SNPs in the human genome. For example, the Aﬀ  ymetrix 
GeneChip 500K platform (Aﬀ  ymetrix, Santa Clara, CA, 
USA) has 68% coverage of the phase II HapMap SNPs at 
r2 of at least 0.8 in the subjects of European ancestry 
(CEU), whereas the Illumina Hap300 platform (Illumina, 
Inc., San Diego, CA, USA) has 77% coverage [49]. Further-
more, coverage is less in non-European populations, up 
to 1% of the common variations are untaggable by other 
SNPs using LD, and there likely exist millions of ‘rare’ 
SNPs not covered by these platforms. Despite their 
limitations, GWASs allowed a higher-resolution screen 
of the human genome for common diseases and traits. In 
the last two years, 11 GWASs in LOAD have been pub-
lished. In this section, brief summaries of each of these 
studies are provided, followed by collective conclusions.
Study-specifi  c characteristics and results of the late-onset 
Alzheimer disease GWASs
Th  e study designs and results of the 11 LOAD GWASs 
are depicted in detail in Tables 1 and 2, respectively 
[50-61]. Th  e  ﬁ  rst published LOAD GWAS used a select 
set of 17,343 SNPs from 11,211 genes that were chosen 
based on their likelihood of being functional poly-
morphisms [50]. Th  ese SNPs were weighted heavily 
toward missense mutations, although there were also 
variants in transcription factor-binding sites, introns, 
intergenic regions as well as other putative functional 
SNPs. Authors used a multi-stage design, in which the 
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Page 4 of 12SNPs were genotyped in pooled DNA from 380 LOAD 
and 396 control subjects in the ﬁ  rst stage. One thousand 
ﬁ  ve hundred forty-four SNPs with AD association at P 
values of less than 0.075 or less than 0.1 and in biological 
candidate genes were genotyped in a second pool of 376 
LOAD and 344 control subjects. Of these SNPs, 119 
showed association at a P value of less than 0.15 with the 
same risk allele associating in the second pool. Th  ese  119 
SNPs were genotyped individually in a total of four series, 
including the two initial pooled series. Eighteen of these 
SNPs that had a P value of less than 0.05 in the two 
pooled series and meta-analysis P value of less than 0.005 
in the four series combined were also genotyped in a ﬁ  fth 
series. Altogether, nearly 4,000 subjects were genotyped 
in this study, although the multi-stage design with two 
pooled DNA series in the initial stages considerably 
reduced the cost of this study. Nonetheless, some asso-
ciations may have been missed due to the reduced 
sensitivity of the pooling approach and the limited 
number of SNPs assessed. Despite these shortcomings, 
APOE-related SNPs (SNPs in APOE or in LD with SNPs 
in APOE) were identiﬁ  ed with study-wide signiﬁ    cance in 
this study. Fifteen additional non-APOE SNPs were 
identiﬁ  ed with nominal signiﬁ  cance after meta-analyses 
of all ﬁ  ve series, with modest ORs of 1.07 to 1.2 in all 
series combined. Of these SNPs, one was a missense 
mutation (rs3745833) in the galanin-like peptide 
pre cursor  (GALP) gene on chromosome 19 which 
showed suggestive study-wide signiﬁ  cance. Th  e galanin 
gene has been implicated in neuronal survival, regenera-
tion, and neuroprotection and inhibition of learning and 
memory through reductions in glutamate release and 
reduction of long-term potentiation (reviewed in [62]). 
Galanin expression has been shown to be upregulated in 
AD brains, although it is unclear whether this is a cause 
or eﬀ  ect. In this study, the authors highlighted additional 
genes among the ﬁ  nal 15 – such as phosphoenolpyruvate 
carboxykinase 1 (PCK1), traﬃ   cking  protein,  kinesin 
binding 2 (TRAK2), and tyrosine kinase, non-receptor 1 
(TNK1) – with potential biological relevance in AD.
Th  e second LOAD GWAS used the Aﬀ  ymetrix 500K 
platform to genotype more than 500,000 SNPs in a histo-
pathologically conﬁ   rmed series of 664 LOAD patients 
and 422 controls and identiﬁ  ed the APOE locus as the 
only region with SNPs that reached genome-wide signi  ﬁ  -
cance after Bonferroni correction for multiple testing 
[51]. Th   e same group reassessed their data by analyzing 
APOE ε4-positive and -negative subjects separately and 
dividing their histopathologic series into discovery and 
replication series [52]. Th  ey focused on 312,316 SNPs 
after quality control exclusions and also included a 
clinical replication cohort in their genotyping and 
analysis. Th  ey  identiﬁ  ed 10 SNPs in the GRB-associated 
binding protein 2 (GAB2) gene on chromosome 11q14.1 
Table 2. Late-onset Alzheimer disease genome-wide association study: summary of results.
  Non-ApoE hits  ApoE-related hits
Reference Gene  symbol  P valuea Odds  ratioa  P valuea Odds  ratioa
Grupe et al. [50]  GALP, TNK1, chr14q32.13, PCK1, LMNA,   0.001 to 5.0 × 10−5  1.07 to 1.2  7.6 × 10−5 to 1.0 × 10−8  1.19 to 2.73
  PGBD1, LOC651924, chr7p15.2, THEM5, 
  MYH13, CTSS, UBD, BCR, AGC1, TRAK2, 
  EBF3
Coon et al. [51]        1.1 × 10−39 4.01
Reiman et al. [52]  GAB2  9.7 × 10−11 4.06  -  -
Li et al. [53]  GOLPH2, chr9p24.3, chr15q21.2  9.8 × 10−3 to 4.5 × 10−6,b  0.46 to 3.23b  2.3 × 10−44 -
Abraham et al. [54]  LRAT  3.4 × 10−6 to 6.1 × 10−7  1.2 to 1.3  4.8 × 10−6 to 4.0 × 10−14 -
Bertram et al. [55]  chr14q31.2, chr19q13.41  6.0 × 10−6 to 2.0 × 10−6  1.1 to 1.4c  5.70 × 10−14 -
Beecham et al. [56]  12q13  3.40 × 10−7 -  -  -
Feulner et al. [57]  MAPT, SORL1, CHRNB2, CH25H,   0.05 to 6.8 × 10−3  -  <1.0 × 10−6 to <1.0 × 10−40 -
  GAB2, PGBD1, PCK1, LMNA
Poduslo et al. [58]  TRPC4AP  3.85 × 10−10 to 5.63 × 10−11,c 1.56d -  -
   0.03d
Carrasquillo  PCDH11X  3.8 × 10−8  1.29  5.9 × 10−6 to  0.55 to 3.29
et al. [59]    (0.08 to 5.4 × 10−13)e  (1.17 to 1.75)e  3.7 × 10−120 
Harold et al. [60]  CLU  8.5 × 10−10 (CLU)  0.86 (CLU)  3.4 × 10−8 to 1.8 × 10−157  0.63 to 2.5
  PICALM  1.3 × 10−9 (PICALM)  0.86 (PICALM)
Lambert et al. [61]  CLU  7.5 × 10−9 (CLU)  0.86 (CLU)  5.06 × 10−7 to <2 × 10−16 -
  CR1  3.7 × 10−9 (CR1)  1.21 (CR1) 
The results of the 11 independent late-onset Alzheimer disease genome-wide association studies are depicted. The results from the original manuscripts shown in 
the table are (a) from all groups combined, (b) shown separately in each series, (c) from the discovery series, (d) from the follow-up case control series, and (e) variable 
based on diff  erent analytical models.
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Page 5 of 12with nominally signiﬁ  cant associations (P = 4.56 × 10−7 to 
8.92 × 10−5) in the APOE ε4 carrier subset of the neuro-
pathological discovery cohort composed of 299 LOAD 
patients and 61 controls. When these 10 SNPs were 
assessed in the APOE ε4-positive subset of the neuro-
pathological replication cohort (113 LOAD patients and 
27 controls) as well as the clinical replication cohort (115 
LOAD patients and 29 controls), 6 of them showed 
nominally signiﬁ   cant associations. Moreover, when all 
three APOE ε4-positive groups were jointly analyzed, 5 
SNPs reached genome-wide signiﬁ  cance after Bonferroni 
corrections, with 1 SNP (rs2373115) achieving P = 9.66 × 
10−11 and OR = 4.06. Th  e GAB2 SNPs did not associate 
signiﬁ  cantly in the APOE ε4 non-carriers, thereby leading 
to reductions in the strength of association when all 
subjects from all series were analyzed collectively as 861 
LOAD patients and 550 controls (rs2373115 SNP 
association had P = 5.56 × 10−4 and OR = 1.66). GAB2 
encodes a scaﬀ  olding protein, GRB-associated binding 
protein 2, which is involved in cell signaling pathways, 
especially in the immune system [63]. Its potential role in 
AD pathophysiology remains to be elucidated; however, 
preliminary functional studies accompanying this LOAD 
GWAS revealed diﬀ  erential expression of GAB2 in AD 
versus control brains, co-localization of GAB2 with 
dystrophic neurites, and variation of GAB2 expression 
inﬂ  uencing tau phosphorylation [52].
Th  e third LOAD GWAS [53] analyzed more than 
400,000 SNPs from the Aﬀ  ymetrix 500K platform in 753 
AD patients and 736 controls from the discovery series 
and followed up the 120 top SNPs in the 418 AD patients 
and 249 controls from the replication series. Th  ey 
identiﬁ  ed APOE-related SNPs with genome-wide signiﬁ  -
cance in the combined series. Of the top 120 associations, 
3 non-APOE SNPs passed their quality control thresholds 
and had nominal logistic regression P value of less than 
0.05 in their replication series. Two of these SNPs, 
rs7019241 and rs10868366, reside in the Golgi phospho-
protein 2 gene (GOLPH2) on chromosome 9, which is in 
a suggestive linkage region [35] and encodes a protein 
functionally involved in Golgi transmembrane traﬃ   cking, 
a subcellular localization where APP cleavage by the γ-
secretase complex occurs [64]. Th   e other SNP, rs9886784, 
resides within a copy number deletion polymorphism on 
chromosome 9. A fourth SNP, rs10519262, which resides 
in an intergenic region on chromosome 15, was identiﬁ  ed 
with the nominal P cutoﬀ   of less than 0.05 using Cox 
proportional hazards regression analysis for age-at-onset 
phenotype.
Using a pooled DNA approach on 1,082 LOAD patients 
and 1,239 controls, the fourth GWAS tested more than 
500,000 SNPs from two Illumina platforms [54]. Th  ese 
SNPs were submitted to three diﬀ  erent analyses to test 
for allelic frequency diﬀ  erences in this pooled population, 
followed by individual genotyping in the same series. 
One hundred fourteen of the 237 chosen SNPs could be 
genotyped individually. In addition to the ﬁ  ve  APOE-
related SNPs with a high level of signiﬁ  cance (P = 8.97 × 
10−5 to 5.89 × 10−9), 74 SNPs had nominal P values of not 
more than 0.05 and were genotyped in an additional 
control group of 1,400 subjects. Although this is not truly 
an independent test, the authors used this approach to 
detect ﬁ  ve  non-APOE SNPs that became even more 
signiﬁ   cant, of which rs727153 had the best P value 
(P = 3.4 × 10−6). Th   is SNP resides in a haplotype block on 
chromosome 4, including the lecithin retinol acyltrans-
ferase gene (LRAT), which is implicated in the retinoid 
pathway [65]. Components of this pathway have been 
suggested to play a role in AD pathogenesis and proposed 
as potential drug targets. Genotyping additional SNPs in 
this study led to improved association signal (rs201825, 
P = 6.12 × 10−7, OR = 1.3) in the overall group, although 
none reached genome-wide signiﬁ  cance after Bonferroni 
correction.
Th  e ﬁ  rst LOAD GWAS to use family-based analysis 
tested more than 400,000 SNPs in 941 AD patients versus 
404 controls from 410 families of European descent [55]. 
Th  e follow-up was done in three series composed of 
1,767 AD patients versus 838 controls from 875 families, 
also of European descent. Th  e authors used a family-
based association approach that assesses disease status 
and age of onset jointly. To obtain the corrected levels of 
signiﬁ   cance, they used not the traditional Bonferroni 
method but a weighted-Bonferroni correction approach 
[66] that ﬁ  rst screens all of the markers and estimates the 
conditional power of each marker, followed by the family-
based association tests that are corrected using the 
weights determined from the screening analysis. Accord-
ing to this paradigm, they detected four non-APOE SNPs 
with P values of 2.0 × 10−3 to 4.0 × 10−6, which would not 
have been signiﬁ   cant after the traditional Bonferroni 
correction. Th   ese four markers had nominal signiﬁ  cance 
of P = 0.3 to 2.0 × 10−5 in the replication series. Th  e  two 
SNPs with nominal signiﬁ   cance in both stages, 
rs11159647 and rs3826656, achieved P values of 2.0 × 
10−6 and 6.0 × 10−6, respectively, for AD association in the 
combined series, which fell short of genome-wide signiﬁ  -
cance after Bonferroni correction. rs11159647 appeared 
to have an eﬀ  ect on age of onset as well. Th   ese SNPs had 
a nominal P value of less than 0.05 in another LOAD 
GWAS [52,53]. rs11159647 on 14q31.2 and rs3826656 on 
chromosome 19q13.33 reside in regions without any 
mapped RefSeq genes, although the latter is in a pre-
dicted gene, which overlaps with the CD33 antigen gene. 
Th   is group also evaluated the top genes from the AlzGene 
database at the time and determined some variants at 
P = 0.03 and 0.002. Notably, GAB2 [52] showed one of the 
strongest nominal association signals.
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Page 6 of 12Th   e sixth LOAD GWAS genotyped more than 500,000 
SNPs from the Illumina HumanHap550 platform in 492 
LOAD cases and 496 controls in addition to imputing 
genotypes using a previously published LOAD GWAS 
[52]. Th  e authors used a modiﬁ   ed false discovery rate 
approach (false discovery rate-beta uniform mixture, or 
FDR-BUM) [67] to declare signiﬁ  cance at the genome-
wide level. Besides APOE-related SNPs, some of which 
would be signiﬁ   cant after Bonferroni correction, 
rs11610206 on 12q13, which does not reside in a RefSeq 
gene, was identiﬁ  ed at genome-wide signiﬁ  cance using 
the more relaxed FDR-BUM criteria (nominal P = 1.93 × 
10−6). When genotyped in the follow-up series of 238 
LOAD and 220 control subjects, this SNP was nominally 
signiﬁ  cant at P = 0.0496 and the signiﬁ  cance in the joint 
series improved to P = 3.452 × 10−7, falling short of 
signiﬁ   cance after Bonferroni correction. Additionally, 
any SNP that had a P value of 0.0001 or less in this study 
or another LOAD GWAS [52], was imputed in the study 
that did not genotype that SNP. Th  ey identiﬁ  ed  eight 
SNPs with a nominal P value of less than 0.05 in the other 
study, in which the joint P value reached 1.51 × 10−6 for 
the most signiﬁ   cant SNP in ZNF224 on chromosome 
19q13. Th  ey also evaluated the AlzGene candidates in 
these two LOAD GWASs by assessing the genotyped or 
imputed SNPs in these genes for association with AD. 
Twenty-ﬁ   ve SNPs from nine genes (ADAM12, CSF1, 
GBP2, KCNMA1, NOS2A,  SORCS2, SORCS3,  SORL1, 
and WWC1) had nominal P values of 0.003 to 0.05 in the 
individual LOAD GWAS with P values of 0.0001 to 0.01 
in the joint analysis. In addition to providing suggestive 
evidence for a number of loci in the genome, this study 
drew attention to the challenges of comparing multiple 
GWASs via impu  tation, in which lack of suﬃ   cient marker 
infor  mation could lead to false-negative results. In these 
two studies, this was the case with the APOE SNPs that 
were highly signiﬁ  cant in each study but could not be 
imputed in the other study, leading to missing the APOE 
signal in the joint analyses.
A single-stage LOAD GWAS from Germany analyzed 
491 AD patients versus 479 younger controls and focused 
on the SNPs for the top 10 genes from AlzGene at the 
time of their study and SORL1. Th  us, although 555,000 
SNPs were genotyped, this study, due to its analytical 
approach, should be considered a follow-up to other 
association studies rather than a hypothesis-generating 
GWAS. Both single SNP and haplotype analyses were 
performed. In addition to APOE-related SNPs, some of 
which achieved genome-wide signiﬁ  cance after Bonferroni 
correction, SNPs in 8 of the 11 genes tested (MAPT, 
SORL1, CHRNB2,  CH25H,  GAB2,  PGBD1, PCK1, and 
LMNA) revealed nominal signiﬁ  cance of P values of 0.05 
to 6.8 × 10−3 in this study. None of the non-APOE SNPs 
achieved genome-wide signiﬁ  cance in their study, but the 
authors provided follow-up analysis results that can be 
used in meta-analyses of all available data on these genes.
Th  e second family-based LOAD GWAS assessed the 
smallest sample size to date, focusing on two extended 
LOAD families with 9 aﬀ  ected and 10 unaﬀ  ected family 
members versus 60 unrelated controls from the CEPH 
(Centre d’Etude du Polymorphisme Humain) collection. 
In stage I, they genotyped more than 400,000 SNPs and 
identiﬁ   ed association with 6 SNPs in the TRPC4AP 
(transient receptor potential cation channel, subfamily C, 
member 4 associated protein) gene at genome-wide 
signi ﬁ    cance (P = 5.63 × 10−11 to 3.85 × 10−10). Because this 
initial analysis compared ADs from families with un-
related controls outside of the families, it cannot be 
considered a family-based analysis. Th  e authors subse-
quently genotyped 10 SNPs in TRPC4AP and identiﬁ  ed a 
common haplotype with increased frequency in the AD 
patients from the families compared with the control 
spouses. Th  e same haplotype was also associated with 
LOAD in an unrelated case control series of 199 LOAD 
versus 85 control subjects. Th  e authors suggest a func-
tional role for this gene in AD through its interaction 
with proteins in the inﬂ  ammatory cascade and its role in 
calcium homeostasis. Despite the genome-wide 
signiﬁ  cant results in this study, the ﬁ  ndings need further 
replication given the small sample sizes and analytic 
approach in the ﬁ  rst stage, which used unrelated controls 
versus AD patients from the families. Indeed, this is the 
only GWAS that failed to identify APOE; this could be 
due to the fact that these families have risk factors that 
are distinct from the general population, but this could 
also suggest lack of suﬃ   cient power.
Th  e third largest LOAD GWAS to date assessed 844 
LOAD subjects versus 1,255 controls in the ﬁ  rst stage, 
which assessed more than 300,000 SNPs on an Illumina 
platform. Th   e authors followed the top 25 SNPs from this 
stage for association in the follow-up series of 1,547 
LOAD subjects versus 1,209 controls. APOE-related 
SNPs were the only ones that were signiﬁ   cant at the 
genome-wide level in the ﬁ   rst stage. Upon combined 
analysis of all samples, rs5984894 in the protocadherin 
11X (PCDH11X) gene on chromosome Xq21.31 was the 
only one that achieved genome-wide signiﬁ  cance (P = 3.8 × 
10−8, OR = 1.29). Multi-variable logistic regression 
analysis using male sex as a covariate and comparing 
male hemizygotes, female heterozygotes, and female 
homozygotes with the female non-carriers yielded global 
a P value of 3.9 × 10−12 for the global association. Male 
hemizygotes showed suggestive association (P = 0.07), 
whereas female heterozygotes and homozygotes had 
nominally signiﬁ  cant associations (P = 0.01 and 2.0 × 
10−7, respectively), with OR estimates of 1.18, 1.26, and 
1.75, respectively, for these groups. PCDH11X is the ﬁ  rst 
X-chromosomal candidate AD gene identiﬁ  ed in a LOAD 
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cadherins that are involved in cell adhesion, cell signaling, 
and neural development. Protocadherins are expressed 
predominantly in the brain, suggesting their potential 
role in brain morphogenesis [68]. Although the func-
tional role of this gene in AD needs to be established and 
the genetic eﬀ  ect conﬁ  rmed through additional studies, it 
is an intriguing hypothesis that this X-chromo  somal gene 
could explain the increased risk of AD in women.
Th  e two most recent LOAD GWASs are by far the 
largest ones published to date in this ﬁ  eld [60,61]. One of 
the two GWASs in LOAD case control series in which 
non-APOE SNPs reached genome-wide signiﬁ  cance after 
Bonferroni correction in the ﬁ  rst stage was performed in 
3,941 LOAD and 7,848 control subjects from 13 diﬀ  erent 
centers in Europe and the US, where up to more than 
500,000 SNPs were analyzed. In addition to the APOE-
related SNPs that revealed genome-wide signiﬁ  cance 
(P = 4.9 × 10−37 to 1.8 × 10−157), rs11136000 in clusterin 
(CLU or ApoJ) on chromosome 8 and rs3851179 in the 
phosphatidylinositol-binding clathrin assembly protein 
(PICALM) gene on chromosome 11 yielded genome-
wide signiﬁ  cance  with  P = 1.4 × 10−9 and 1.9 × 10−8, 
respectively. When genotyped in the follow-up series of 
2,023 LOAD versus 2,340 control subjects from ﬁ  ve 
centers in Europe, these SNPs had nominal signiﬁ  cance 
at a P value of less than 0.05. Signiﬁ  cance for rs11136000 
in CLU improved to P = 8.5 × 10−10 (OR = 0.86) and that 
for PICALM improved to P = 1.3 × 10−9 (OR = 0.90) in 
the combined series. In addition, the authors identiﬁ  ed 
more SNPs than would be expected by chance with P 
values of less than 1.0 × 10−5, including an SNP in the 
complement receptor 1 gene (rs1408077) that was 
identiﬁ   ed at genome-wide signiﬁ   cance in the other 
largest LOAD GWAS to date [61] (P = 8.3 × 10−6). Th  e 
authors tested more than 100 SNPs in their series that 
were identiﬁ  ed in other LOAD GWASs and identiﬁ  ed 
nominal signiﬁ  cance at a P value of less than 0.05 for a 
number of these, including PCDH11X and SORL1.
Th  e other large LOAD GWAS analyzed more than 
500,000 SNPs in 2,032 LOAD versus 5,328 control 
subjects from France [61]. Like the other large LOAD 
GWASs, this study identiﬁ  ed rs11136000 in CLU with 
genome-wide signiﬁ  cance in the ﬁ  rst stage (P = 9.0 × 
10−8) in their analysis, correcting for population stratiﬁ  -
cation in addition to APOE-related markers (P = 5.06 × 
10−7 to less than 2 × 10−16). Th   ose SNPs with a P value of 
less than 1.0 × 10−5 were genotyped or imputed in the 
follow-up series composed of 3,978 LOAD versus 3,297 
controls from 15 centers in four countries. CLU SNP 
rs11136000 had nominal signiﬁ  cance in their second stage 
and enhanced signiﬁ  cance of P = 7.5 × 10−9 (OR = 0.86) in 
their combined series. Another SNP, rs6656401, in 
complement component receptor 1 (CR1) also achieved 
genome-wide signiﬁ  cance in the combined series with 
P = 3.7 × 10−9 (OR = 1.21). Th  e authors also identiﬁ  ed 
nominal signiﬁ  cance for SNPs in PICALM (P = 1.0 × 10−2 
to 1.0 × 10−3) and PCDH11X (0.01 < P < 0.05) in their series, 
thereby providing additional evidence for these genes 
identiﬁ  ed in other LOAD GWASs [59,60].
CLU encodes clusterin or ApoJ, which along with 
APOE is one of the most abundant apolipoproteins in the 
human brain. In vivo studies suggest that clusterin, like 
APOE, is involved in Aβ clearance from the brain 
(reviewed in [33]). Th   ere are also studies that revealed a 
role for clusterin in Aβ ﬁ  brillogenesis and neurotoxicity. 
Th  ese results raise the possibility that, in Aβ patho-
physiology, clusterin may have a dual role similar to that 
of  APOE.  PICALM encodes a protein involved in 
clathrin-mediated endocytosis, a suggested pathway for 
traﬃ   cking of APP that could also inﬂ  uence Aβ formation 
[69]. Th  ere is also evidence that PICALM inﬂ  uences 
endocytosis of the synaptic vesicle protein VAMP2 from 
the plasma mem  brane [70], suggesting a role in synaptic 
function. CR1 is a receptor for the complement compo-
nent C3b, which has been suggested to be involved in the 
peripheral clearance of Aβ [71]. Th   us, all three candidate 
genes that emerged from the two largest LOAD GWASs to 
date have putative functions in the Aβ cascade and 
synaptic machinery (for PICALM). Additional non-Aβ-
mediated pathophysiologic mechanisms for the proteins 
encoded by these genes may exist and require further 
investigation.
It is important to note that a number of the ‘hits’ 
identiﬁ  ed from the LOAD GWASs reside in prior linkage 
regions (for example, GALP on chromosome 19, LMNA 
on chromosome 1, GOLPH2 on chromosome 9, and CLU 
on chromosome 8) and that others (such as MAPT and 
SORL1) have previously been implicated in candidate 
gene association studies. Multiple lines of evidence in 
support of the same gene provide additional support for 
their role in the risk of AD; however, in general, these 
results need to be interpreted with caution and special 
attention to any sample overlaps, eﬀ  ect size, and direction 
of eﬀ  ect in the diﬀ  erent studies. Th  e AlzGene database 
facilitates the visualization and cross-checking of ﬁ  ndings 
from diﬀ  erent linkage and association studies [29].
Cumulative results from late-onset Alzheimer disease 
GWAS
GWASs in LOAD led to the generation of a multitude of 
novel candidate genes for follow-up. Table 3 depicts the 
list of genes and variants with the strongest level of 
association in these studies. Th   e most consistent pattern 
that emerges from this table is that the eﬀ  ect size and 
strength of association for APOE-related variants are 
greater than the best non-APOE associations. Th  ere  are 
multiple explanations for this ﬁ  nding: It is possible that 
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Page 9 of 12all LOAD risk variants are common with modest eﬀ  ect 
sizes, as suggested by Table 3. However, the ﬁ  ndings from 
the GWASs are, for the most part, not based on the true 
susceptibility variants but are reﬂ  ective of their tagging 
markers, which may harbor greater heterogeneity than 
the former with respect to alleles and extent of LD. Th  us, 
it remains a possibility that the actual functional suscep-
tibility variants may have bigger eﬀ   ect sizes. Another 
possibility is the existence of rare variants with bigger 
eﬀ  ect sizes underlying risk of LOAD, particularly given 
the insuﬃ   cient coverage of the rare variants in the human 
genome with the current GWAS platforms.
Table 3 provides estimates of the PARs of the strongest 
APOE and non-APOE variants from the existing GWASs, 
where necessary information is available. PARs for the 
APOE-related variants vary between 19% and 35%. Th  e 
PAR estimates for the three genes identiﬁ  ed from the two 
largest LOAD GWASs to date are approximately 9% for 
CLU and PICALM and 4% for CR1. Th  e  eﬀ  ect sizes from 
the original studies tend to be overestimates. A number 
of the GWAS hits were assessed in independent studies 
summarized in AlzGene, in which estimates from meta-
analysis may be closer to the true eﬀ  ect sizes of genetic 
variants in the population. As seen in Table 3, PAR 
estimates of GALP, GAB2, PICALM, and CR1 decreased 
upon analyses of additional series, although that of CLU 
increased slightly. Replication studies with a thousand to 
tens of thousands of subjects are required to validate 
these ﬁ   ndings and obtain more accurate estimates of 
eﬀ   ect sizes. Th  e current combined LOAD PARs for 
APOE, CLU, PICALM, and CR1 are approximately 56% 
at most. Given that genetic factors underlie up to 80% of 
the risk for LOAD [4], the remaining genetic risk for AD 
could be due to variants in other genes such as PCDH11X 
or GAB2, rare or structural variants, presence of diﬀ  erent 
genetic factors in non-European populations, and/or 
gene-gene and gene-environment interactions.
Conclusions and future directions in the 
post-GWAS era
Discoveries in the sequence and structure of the human 
genome, technical advances in high-throughput geno-
typing, and development of novel analytical approaches 
led to an explosion in the number and extent of genetic 
studies in common, complex diseases such as LOAD. 
Numerous candidate genes that emerged from these 
studies require further validation not only via genetic 
replication but also through functional assessment by in 
vitro and in vivo approaches. Experience from other 
common, complex diseases suggests that, despite their 
success in uncovering common genetic factors for 
complex diseases, GWASs may fall short of explaining all 
of the underlying genetics [72] because of their limita-
tions discussed earlier. Th  us, alternative approaches are 
necessary to identify the remaining genetic susceptibility 
factors. To identify the actual functional variations 
responsible for the current association and linkage 
signals as well as to detect rare and structural variations 
in candidate regions, next-generation sequencing is 
emerging as a promising approach. Additionally, novel 
analytical approaches that can mine available GWAS data 
may uncover structural variations (such as insertions, 
deletions, translocations, and inversions) that are 
associated with disease. Indeed, novel approaches that 
can re-assess GWAS results may provide an eﬃ   cient 
method to generate novel information. Combining 
biologically relevant quantitative phenotype (endopheno-
type) and GWAS data may be a powerful approach that 
can potentially lead to the identiﬁ  cation of genetic factors 
that inﬂ   uence disease risk and plausible biological 
pathways. It will also be important to jointly assess the 
results of GWASs and other large-scale association and 
linkage studies to capitalize on the cumulative knowledge 
that can be gained from such meta-analyses [73]. Recent 
advances in the genetics of LOAD provide promise in 
furthering our understanding of its pathophysiology. 
With the new discoveries in genomics, genetic studies in 
the post-GWAS era hold potential for uncovering the 
complex susceptibility factors for this disease which may 
translate into therapeutic potential for this devastating 
epidemic.
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